Thyrocare Technologies Ltd · NSE:THYROCARE
Thyrocare Technologies — Q1 FY2022 Earnings Presentation
13 slides from Thyrocare Technologies's earnings presentation, Aug 13, 2021
Slide 1: Thyrocare – Presentation on Quarterly Results
Thyrocare’ The Trust. The Truth. August 13, 2021 A Koy National Stock Exchange of India Limited BSE Limited Exchange Plaza Phiroze Jeejeeboy Towers Bandra Kurla Complex, Dalal Street, Bandra (E), Mumbai - 400 051 Mumbai- 400 001 Dear Sirs, Sub: Presentation on Quarterly Results for the quarter ended
Slide 2: Quarterly Presentation – June 2021
Thyrocare Technologies Limited Quarterly Presentation – June 2021
Slide 3: Contents
Contents Key Highlights – pathology 1 Key performance indicators – pathology 2 Income Statement – Thyrocare 3 Revenue – source 4 Revenue – type 5 Revenue – geography 6 Income Statement – Nueclear 7 Revenue – centrewise 8 Income Statement – Consolidated 9 Disclaimer This presentation is for informati
Slide 4: Key Highlights - pathology
Key Highlights - pathology 1 Revenue EBITDA Margins PAT Margins ` 159 Cr ↑14%* ` 70 Cr 44% ` 48 Cr 30% Aarogyam Sickness COVID RTPCR Free Cash Available ` 58 Cr Samples Samples Processed 5.09 lacs 36.96 lacs 11.38 Lac * Sequential quarter
Slide 5: Key performance indicators - pathology
Key performance indicators - pathology 2 Revenue (in crore) and EBITDA Diagnostic revenue by source Diagnostic revenue by nature (in Margin (%) (in crore) crore) 200.0 43% 44% 50% 200.0 200.0 36% 26.14 40% 150.0 150.0 12.91 150.0 30% 55.20 23.27 100.0 100.0 0.72 30.66 100.0 64.68 17% 20% 20.01 36.17
Slide 6: Income Statement - Thyrocare
Income Statement - Thyrocare 3 YOY Revenue growth of 193% was primarily on account nationwide lockdown implemented during last year and erosion of business in april and may of previous FY. Sequential quarter Revenue growth of 14.4% was primarily on account of COVID testing of Rs. 45.4 crore. Covid r
Slide 7: Revenue - source
Revenue - source 4 Revenue growth in the current quarter was significantly contributed by the surge in revenue from COVID tests. Covid revenue of Rs. 45.40 crore constitutes 30% of reported revenue, generated from 1.19 million COVID tests performed during the current quarter Total Revenue (in crore)
Slide 8: Revenue – type
Revenue – type 5 Preventive care profiles under ‘Aarogyam’ contributed to 24% of total reported revenue in Q1. Covid constitutes 30%, Covid antibodies contributed 6% and other sickness tests contributed 64% of total reported revenue in Q1. Average realization per sample for Aaorgyam profiles Diagn
Slide 9: Revenue - geography
Revenue - geography 6 Geographically west region contributes 71% of COVID RTPCR revenue and 35% of Non Covid revenue. Non COVID revenue % terms reviving back to pre covid contribution. Revenue by geography INR in crore Revenue Mix % Var Q-June19 Q-June20 Q-June21 Q-June19 Q-June20 Q-June21 COVID OTH
Slide 10: Income Statement - Nueclear
Income Statement - Nueclear 7 Radiology business accounted for 3% of reported consolidated revenue of Thyrocare Group in current quarter. The contribution of radiology revenue has not increased despite of improvement in scan volumes, primarily due to increase in pathology revenue due to contribution
Slide 11: Revenue - centrewise
Revenue - centrewise 8 PET CT revenue revived after covid and subsequent lockdown impact in the current quarter with newer centre contributing in the imaging revenue was significantly impacted by 2nd wave. Nueclear has decided to either transfer/ close down centres with low scan count or with high e
Slide 12: Income Statement - Consolidated
Income Statement - Consolidated 9 Revenue growth of 12% (sequentially) in current quarter was primarily on account of COVID RT-PCR testing of Rs. 45.40 Crore, Covid antibodies and Covid related parameters of Rs. 16.07 crore; Non-COVID diagnostics revenue and imaging revenue decreased by 15% and 30%
Slide 13: Thank You
Thank You 1500+ 280+ 60000+ 20000+ 20-24 HOURS EMPLOYEES DISTRICTS TOUCH POINTS PARTNERS AVERAGE SAMPLE PROCESSING TIME
Thyrocare Technologies — Q1 FY2022 Earnings Presentation on 6ix